Micro-quantity florescent detection instrument TL998A
Introduce

The Fluorescence Detection System for end-point QPCR (FDS) provides an economical solution of end-point quantitative PCR detection after PCR cycling. The real-time quantitative PCR detection system is more expensive than the FDS plus the PCR cycler. The FDS can be connected with computers via RS232C serial interface. The powerful and easy-operating software supplies many functions such as data procession and analyzer, medical case statistic, database management and so on. Additional, customers can get remote guide and remote quantity-control through the Internet if they connect the FDS with computer.

Key Features

• End-point quantitative PCR detection.

• Specially designed for PCR cycler.

• Can be connected with computer via RS232C interface.

• Powerful software, supply data procession and analysis, medical case statistic, database management.

• Remote guide and remote quality-control enable.

• Operating easy.

High reliability and economy.

Specification

Reagents	FAM, FITC, SYBR. various fluorescence PCR reagents, such as TaqMan probe, etc.
Sample volume	20-100 μl
Wavelength of exciting fluorescence	470 nm
Wavelength of fluorescence detection	530 nm (changeable)
Monochromator device	Filter, made in USA
Photo Detector	PMT (Photomultipier tube), made in Japan
Correlative coefficient	R ≥ 0.96
Test Precision	0.1 RLU
Display	High-light LCD, 20 × 2 pixel
Data communication interface	Connected with computer via RS232C interface
Light source	LED
Input power	AC 220 ± 22 V ， 50 ± 1 Hz
Power	60 W
Size	500 mm × 350 mm × 200 mm
Weight	6 ㎏
Operating environment	Ambient Temperature 5 °C -40 °C Relative Humidity 30%-70%

Since its establishment in 1997, Tianlong has been committed to the research and development, production and overall solutions of instruments and in vitro diagnostic reagents in the field of genetic testing and molecular diagnostics. With its own sustainable development and potential values, Tianlong has received investments from SK Group, the 57th largest company in the Fortune Global 500 list, and Kehua Bio-Engineering, a listed company in China, in 2012 and 2018.



As a high-tech enterprise in China, Tianlong Technology is responsible for many major scientific research and industrialization projects such as the National Key Research and Development Program, the National Special Project for the Development of Major Scientific Instruments and Equipment, and the National Science and Technology Support Program. ISO9001-certified and 13485-standard, Tianlong now has hundreds of products such as nucleic acid extractor, automated nucleic acid workstation, gene amplification instruments, real-time PCR instruments, ATP fluorescence detector and supporting test reagents. over 50 products have been approved by NMPA with medical device registration certificates, and more than 20 products have been approved by EU (CE) and KFDA (South Korea).



Tianlong products are widely applied in the fields of medical diagnosis, food safety, epidemic prevention and control, customs and quarantine, forensics, scientific research, etc., and have contributed to the prevention and control of various major epidemics such as avian flu, Ebola, MERS, African swine fever and neonatal pneumonia. At present, Tianlong is serving more than 2,000 customers in more than 40 countries and regions including, Korea, the United States, France, Germany, Denmark, the United Arab Emirates, Pakistan, and so on.



At the end of 2019, after the outbreak of the COVID-19 epidemic, Tianlong quickly launched SARS-CoV-2 rapid nucleic acid detection solution, successively detected the first positive samples in many provinces in China, and made a great contribution to the epidemic prevention and control globally. Tianlong successively received letters of thanks from the State Council of China, the National Center for Disease Control of China, and the Slovakian government. Tianlong was then reported by CCTV News, Xinhua News Agency, People's Daily and other authoritative media.



In the face of future opportunities and challenges, we will continue to create first-class molecular diagnostic products and work hard for human health in a more open way of cooperation with all walks of life.